Purchase this article with an account.
Tai Kyong Kim, Young-Hoon Park; Effect of Topical Non-Steroidal Anti-Inflammatory Drugs on HLA-B27 Associated Uveitis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1866.
Download citation file:
© 2017 Association for Research in Vision and Ophthalmology.
Some studies indicated that oral non-steroidal anti-inflammatory drugs (NSAIDs) therapy is useful in the long-term management of patients with HLA-B27 associated acute anterior uveitis (AAU). But few address the role of the topical NSAIDs in prevention of recurrences in these diseases. The objective of our study is to evaluate the effect of topical NSAID on HLA-B27 associated AAU.
By retrospective chart review, from Jan 2008 to Dec 2013, we included 60 patients of HLA-B27 associated uveitis who were treated by topical NSAID, diclofenac and 60 other patients of HLA-B27 associated uveitis who were not treated by diclofenac. We investigated and compared the amount of time to recovery in AAU, severity of inflammation in the anterior chamber, remission period, complications (glaucoma, posterior synechiae, macular edema) in each group. Patients are divided into three subgroups (who were treated only by topical eyedrops, treated by oral steroid and treated by immunosuppressants drugs or anti-TNF-α agents). Previously mentioned factors were also compared between diclofenac and non diclofenac groups in these subgroups.
The difference in the duration of AAU, severity of inflammation in the anterior chamber, remission period, complications in both groups were not statistically significant between two groups. In the subgroup analysis of patients treated by immunosuppressants drugs or anti-TNF-α agents, average remission period was 24 months in the diclofenac group and 14 months in the non-diclofenac group respectively and it was statistically significantly longer in the diclofenac group (p=0.001).
In HLA-B27 associated AAU, it is supposed that topical diclofenac can prolong the remission period in patients treated by immunosuppressants drugs or anti-TNF-α agents.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only